← All trials
NCT04400799
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2020
- Primary completion
- Mar 14, 2021
- Completion date
- Apr 14, 2021
- First posted
- May 25, 2020
- Last posted
- May 25, 2020
- Enrollment
- 1000
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of ZurichLead sponsor
- University of BernCollaborator
- University of ZurichOverall official - principal investigator
- University of ZurichReponsible party - principal investigator
- University of BaselCollaborator
- University of GenevaCollaborator
- University of LausanneCollaborator
- Ospedale S. Giovanni BellinzonaCollaborator
- Clinica Luganese MoncuccoCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.